Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose de-escalation of filgotinib in ulcerative colitis patients in stable clinical remission
2022-000719-30Phase 3Completed
- Sponsor
- Galapagos NV
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in autoimmune colitis (2 arms), sponsored by Galapagos NV. Primary endpoint: Proportion of subjects in corticosteroid-free clinical remission based on modified Mayo Clinical Score. Started Jul 2022; status: completed.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-000719-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000719-30.